Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Charcot-Marie-Tooth Disease
Interventions
DRUG

NMD670

Tablets taken twice daily for 21 days

DRUG

Placebo

Tablets taken twice daily for 21 days

Trial Locations (19)

3000

University Hospitals Leuven, Department of Neurology, Leuven

4000

CHR de la Citadelle- Site Citadelle Neurolgie Boulevard du 12eme de Ligne 1, Liège

8035

Hospital Universitari Vall d'Hebron, Barcelona

10032

Columbia University Medical Center, New York

13005

CHU Marseille, Reference centre for neuromuscular diseases and ALS Department of Neuromuscular Diseases, Marseille

14642

University of Rochester Neuromuscular Disease Center, Rochester

43221

OSU Department of Neurology Division of Neuromuscular Diseases, Columbus

46026

Hospital Universitari i Politecnic La Fe de Valencia, Valencia

65211

NextGen Precision Health, Columbia

66160

University of Kansas Medical Center, Department of Neurology, Kansas City

75651

Institut de Myologie Groupe Hospitalier Pitié-Salpêtrière, Paris

78759

National Neuromuscular research Institute, PLLC, Austin

94275

Bicêtre University Hospital, Paris

99204

Providence Medical Research Center, Spokane

02114

Mass General Neurology, Boston

Unknown

Aarhus University Hospital, Aarhus

Rigshospitalet, Department of Neurology, Copenhagen

Laboratoire d'Explorations Fonctionnelles, CHU Nantes, Nantes

06001

Centre Hospitalier Universitaire De Nice, Nice

Sponsors

Lead Sponsor

All Listed Sponsors
lead

NMD Pharma A/S

INDUSTRY

NCT06482437 - Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease | Biotech Hunter | Biotech Hunter